OBJECTIVES: To evaluate the cost-effectiveness of a rheolytic thrombectomy system for the treatment of deep vein thrombosis in Mexican adult patients, based on quality adjusted life years (QALYs) and number of pulmonary embolism (PE) avoided. METHODS: We constructed a Markov model to project a hypothetical cohort of adult patients diagnosed with deep vein thrombosis (DVT). We calculated the incremental cost-effectiveness ratio (ICER) of the rheolytic thrombectomy system in comparison with rivaroxaban, warfarin, enoxaparin, fondaparinux, nadroparin, and tinzaparin. Alternatives were considered cost-effective when the ICER was equivalent or below the value of one gross domestic product (USD $8,902), this based on the norms of the Mexican HTA agency. Direct medical costs were obtained from Mexican Social Security Institute (IMSS) and transition probabilities were extracted from randomized clinical trials and cohort studies; all costs are expressed as 2018 value of the United States dollars. The time horizon was lifetime, therefore both costs and outcomes were discounted at 5%, the cycles length were 3 months. Sensitivity analyses were estimated with Monte Carlo simulations. The analysis leveraged TreeAge™ Software. RESULTS: The ICER for the rheolytic thrombectomy system in comparison with rivaroxaban was USD$ 3,834 per QALY gained and USD$ 3,608 per PE avoided. In comparison with, warfarin, enoxaparin, fondaparinux, nadroparin, and tinzaparin the rheolytic thrombectomy system is ‘dominant’ strategy. CONCLUSIONS: This is the first economic study analyzing the performance of a rheolytic thrombectomy system in Mexican patients diagnosed with DVT. Our results suggest that the rheolytic thrombectomy system is projected to provide a very cost-effective treatment and estimated to likely be cost-saving compared to an alternative pharmacological treatment.